PMV
PMV Do and dare company
mute

PMV is a do and dare company that is shaping the future of the Flemish economy.

PMV provides finance for promising businesses, from their very start, through their various growth stages and even on to operating internationally.

Working with and for the government and other partners, PMV implements projects that are important for prosperity and wellbeing in Flanders.

PMV coordinates the investment funds of the European Fund for Strategic Investments (EFSI) in Flanders

PMV is the contact point for every enquire for the Juncker Plan, officially the "European Fund for Strategic Investments" (EFSI).

More info

News

28
/03

Oxypoint successfully raises €3.8 million in series A funding

Antwerp, March 28th, 2018 - Oxypoint nv, the award-winning University of Antwerp spin-off, bringing innovation to the medical device market for oxygen therapy in hospitals, announced today the closing of a €3.8 million Series A financing round led by the Flemish investment company PMV, together with a family office. The investment round was guided by Wouter Van Roost, who was appointed CEO of the company. The company will use the proceeds to bring its unique proprietary CE-labelled Econo-Comfort™ Oxygen Flowmeter to the European market and to further expand its product range of novel oxygen-therapy administering medical devices.

portfolio

Trod Medical

Trod Medical
Testimonial: 
Dankzij de de EnCage-technologie van TROD Medical kan er een heel precieze radiofrequentie (RF) ablatie gebeuren van kankerweefsel in de prostaat.

Amakem

Amakem
Testimonial: 
Amakem is een Limburgs farmabedrijf dat innovatieve behandelingen ontwikkelt tegen oogziektes. Hun belangrijkste programma is het onderzoek van kinase-inhibitoren, of middelen die eiwitten helpen hun werk als antistoffen beter te doen.

Formac

Formac Pharmaceuticals
Testimonial: 
Formac is een spin-off van de Universiteit Leuven die zich focust op de formulering van slechte wateroplosbare geneesmiddelen.

FF Pharma

FF Pharma
Testimonial: 
FF Pharma is een biofarmaceutisch bedrijf dat werd opgericht in 2012. FF Pharma ontwikkelt een anti-CD40 monoclonaal antilichaam therapie voor de behandeling van chronische inflammatoire aandoeningen.